September 30, 2016 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Chemtura Corp (NYSE:CHMT), was announced concerning whether the takeover of Chemtura Corp. by LANXESS AG for $33.50 per share is unfair to NYSE:CHMT stockholders.

The investigation by a law firm concerns whether certain directors of Chemtura Corp breached their fiduciary duties owed to NYSE:CHMT investors in connection with the proposed acquisition.

On September 25, 2016, Chemtura Corp (NYSE:CHMT) announced that it has entered into an agreement pursuant to which LANXESS AG will acquire Chemtura Corp (NYSE:CHMT) in a transaction valued at approximately $2.5 billion. Under the terms of the agreement, Chemtura Corp (NYSE:CHMT) shareholders will receive $33.50 per share in cash for each outstanding share of common stock held.

However, given that at least one analyst has set the high target price for NYSE:CHMT shares at $35.00 per share, the investigation concerns whether the offer is unfair to NYSE:CHMT stockholders. More specifically, the investigation concerns whether the Chemtura Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.